This is evidence to support the case for a substance known as VEGF as representing a significant and reproducible marker for the sadly adverse indication in resected (ie surgically removed ) Pancreatic Cancer.
It is a literature review and statistical analysis of existing data conducted by a team including Prof John Neoptholemous ( Liverpool) who is generously providing valuable information and support to the PCUK funded 'Study for Survival'
(http://www.pancreaticcancer.org.uk/stud ... l_home.htm )
Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Related Articles
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.
Br J Cancer. 2011 Mar 29;. [Epub ahead of print]
PMID: 21448172 [PubMed - as supplied by publisher]
Includes VEGF, p53, p16,Smad4,bcl.bax, EGFR
This forum contains news that Pancreatic Cancer UK and forum users have shared over the years.
1 post • Page 1 of 1